US 11,725,048 B2
CXCL10 binding proteins and compositions thereof
Andrew N. Stephens, Knoxfield (AU); Adam Rainczuk, Belgrave (AU); and Sung-Woog Kang, Malvern East (AU)
Assigned to Hudson Institute of Medical Research
Appl. No. 17/783,528
Filed by Hudson Institute of Medical Research, Clayton (AU)
PCT Filed Dec. 18, 2020, PCT No. PCT/AU2020/051403
§ 371(c)(1), (2) Date Jun. 8, 2022,
PCT Pub. No. WO2021/119761, PCT Pub. Date Jun. 24, 2021.
Claims priority of application No. 2019904859 (AU), filed on Dec. 20, 2019.
Prior Publication US 2023/0051580 A1, Feb. 16, 2023
Int. Cl. C07K 16/24 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/24 (2013.01) [G01N 33/57449 (2013.01); C07K 2317/34 (2013.01); C07K 2317/92 (2013.01); G01N 2333/521 (2013.01)] 4 Claims
 
1. An isolated C-X-C motif chemokine ligand 10 (CXCL10) binding protein, wherein the binding protein comprises a variable region of an immunoglobulin or an antigen-binding domain of an antibody and binds to full-length human CXCL10 with a KD of 50 nM or less, but does not bind N-terminally truncated CXCL10 and, wherein the binding protein requires the N-terminal valine and/or proline of the epitope NH2-VPLSRTVRCTCISISNQPVNPRSLE-COOH) (SEQ ID NO: 25) to bind to full-length human CXCL10, wherein the binding protein is an antibody or antigen-binding fragment thereof comprising:
(A)(i) a heavy chain variable region (VH) comprising:
a) a complementarity determining region (CDR) 1 comprising a sequence set forth in amino acids 25-34 of SEQ ID NO: 3;
b) a CDR2 comprising a sequence set forth in amino acids 49-65 of SEQ ID NO: 3; and
c) a CDR3 comprising a sequence set forth in amino acids 98-108 of SEQ ID NO: 3; and
(ii) a light chain variable region (VL) comprising:
a) a CDR1 comprising a sequence set forth in amino acids 23-33 of SEQ ID NO: 4;
b) a CDR2 comprising a sequence set forth in amino acids 49-55 of SEQ ID NO: 4; and
c) a CDR3 comprising a sequence set forth in amino acids 88-96 of SEQ ID NO: 4; or
(B)(i) a VH comprising:
a) a CDR1 comprising a sequence set forth in SEQ ID NO: 5;
b) a CDR2 comprising a sequence set forth in SEQ ID NO: 6; and
c) a CDR3 comprising a sequence set forth in SEQ ID NO: 7; and
(ii) a VL comprising:
a) a CDR1 comprising a sequence set forth in SEQ ID NO: 8;
b) a CDR2 comprising a sequence set forth in SEQ ID NO: 9; and
c) a CDR3 comprising a sequence set forth in SEQ ID NO: 10.